A. Raimondi

2141P Real world-data on neoadjuvant/definitive immunotherapy (IO) or chemo-immunotherapy (CT-IO) in patients (pts) with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) resectable or potentially resectable gastric/gastroesophageal junction (GEJ) carcinoma

Roberta Fazio, G. Di Liberti, Sabina Murgioni, S. Lonardi et autres

it, gr (code pays fourni par la source)

39P AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual patient data (IPD) pooled analysis of randomized clinical trials (RCTs)

A. Raimondi, Giovanni Tinè, Alfonso De Stefano, Alexej Ballhausen et autres

it, de, fr (code pays fourni par la source)

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

A. Raimondi, Sara Lonardi, Sabina Murgioni, Giovanni Gerardo Cardellino et autres

BACKGROUND: In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit from chemotherapy. Immunotherapy may eliminate the need for chemotherapy or surgery. PATIENTS AND METHODS: INFINITY is a multicenter, multicohort phase II trial (NCT04817826) investigating in cohort 1 …

it, us (code pays fourni par la source)

112P The presence of liver metastases does not predict resistance to immunotherapy in proficient MMR metastatic colorectal cancer (mCRC): A secondary analysis of the AtezoTRIBE study

Martina Carullo, C. Antoniotti, Daniele Rossini, Federica Marmorino et autres

it, fr (code pays fourni par la source)

Targeted therapy in cholangiocarcinoma: current landscape and future horizon

C.C. Pircher, Caterina Sposetti, F. Nichetti, F. Corti et autres

Cholangiocarcinoma (CCA) is a malignant disease of the biliary tree which accounts for 15% of primary liver cancers and 3% of gastrointestinal malignancies. For almost a decade, palliative chemotherapy remained the standard of care for advanced CCA with only modest disease control …

it, fr (code pays fourni par la source)